GENFLOW BIOSCIENCES PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.85 GBX | +1.37% |
|
-9.76% | +29.82% |
| May. 08 | Home REIT cuts borrowings, Genflow shares restored | AN |
| May. 08 | Genflow Biosciences Resumes London Trading | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2022 | - | Sales 2023 | - | Capitalization | 4.17M |
|---|---|---|---|---|---|
| Net income 2022 | -1M | Net income 2023 | -1M | EV / Sales 2022 | - |
| Net cash position 2022 | 2.36M | Net cash position 2023 | 684K | EV / Sales 2023 | - |
| P/E ratio 2022 |
-5.26
x | P/E ratio 2023 |
-2.56
x | Employees | 5 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 36.34% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +1.37% | ||
| 1 week | -9.76% | ||
| Current month | -9.76% | ||
| 1 month | +13.85% | ||
| 3 months | +19.35% | ||
| 6 months | +15.62% | ||
| Current year | +29.82% |
1 week
1.80
2.29
1 month
1.502.29
Current year
1.322.29
1 year
1.323.90
3 years
1.3213.50
5 years
1.3213.50
10 years
1.3213.50
| Managers | Title | Age | Since |
|---|---|---|---|
| Founder | 66 | 19-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 64 | 22-06-28 | |
Tamara Joseph
CHM | Chairman | 61 | 22-06-28 |
| Founder | 66 | 19-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-10 | 1.85 | +1.37% | 1,451,083 |
| 24-05-09 | 1.825 | -8.75% | 2,489,384 |
Delayed Quote London S.E., May 10, 2024 at 11:35 am EDT
More quotes
Genflow Biosciences Plc is a United Kingdom-based biotechnology company. The Company is engaged in developing gene therapies designed to target the aging process and to reduce and delay the incidence of age-related diseases, which is done through therapeutics targeting aging in humans by using adeno-associated virus (AAV) vectors to deliver copies of the Sirtuin-6 (SIRT6) gene variant that is found in centenarians into cells. The Company's product line includes GF-1002, GF-3001 and GF-4001. GF-4001. GF-1002 is a suspension of an adeno-associated viral vector-based gene therapy for intravenous infusion. GF-4001 is a non-human version of GF-1002 anti-ageing gene therapy developed for veterinary use (dogs). GF-3001 is a formulation of an adeno-associated viral vector-based gene therapy. The Company has operations in the United Kingdom and Belgium.
Calendar
2024-09-26
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +29.82% | 8.1M | |
| +3.91% | 109B | |
| +10.87% | 105B | |
| +1.28% | 22.25B | |
| -13.14% | 22.09B | |
| -7.05% | 18.68B | |
| -38.36% | 17.58B | |
| -10.66% | 16.85B | |
| +3.75% | 13.76B | |
| +36.70% | 12.46B |
- Stock Market
- Equities
- GENF Stock